ReviewTherapeutic advances in chronic disease2018

Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential.

Michael E RøderPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.